NRX Pharmaceuticals, Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.3541 USD
−25.13 M USD
0.00 USD
26.18 M
About NRX Pharmaceuticals, Inc.
Sector
Industry
CEO
Jonathan C. Javitt
Website
Headquarters
Wilmington
Founded
2017
Identifiers
3
ISIN US6294441182
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.
Displays a symbol's price movements over previous years to identify recurring trends.